| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to a compound of formula 1 where R is hydrogen or a C 1-4 -alkyl group; R 1 means a group selected from the group consisting of structures represented by formulas (Ia), where R 2 means hydrogen or a C 1-4 -alkyl group; R 3 means hydrogen, a halogen, CF 3 , CN or C 1-4 -alkyl and R 4 means hydrogen, a halogen or a C 1-4 -alkyl; a=0, 1, or 2; b=0, 1, 2 or 3; C=1, 2 or 3, and R a , R b , R c and R d represent, independently of one another, H or a C 1-4 -alkyl; X means a C 2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a hetero-atom selected from O and S, or CH(CH 2 )CH-; Y means hydrogen, a halogen, a C 1-4 -alkyl, C 1-4 -alcoxy or C 1-4 -hydroxyalkyl; Z means a C 1-4 -aliphatic hydrocarbon bridge optionally containing one double bond and/or one hetero-atom selected from O, S, N and N(CH 3 ), or means a C 2-4 -aliphatic hydrocarbon bridge fused with a C 3-6 -cycloalkyl, optionally containing one or more double bonds or with a phenyl ring, or means a C 1-4 -aliphatic hydrocarbon bridge substituted with a spiro-C 3-6 -cycloalkyl, optionally containing one or more double bonds; or its pharmaceutically acceptable salt, or a stereoisomer, or a pharmaceutically acceptable salt of the stereoisomer. The compounds according to the invention are obtained due to reductive amination of the benzaldehyde of formula 4 by means of a primary amine R 1 -NH 2 , the introduction in the interaction of the obtained secondary amine of formula 2 with ether formyl - or oxocyclohexanecarboxylic acid of formula 3, where X, Y, Z, R 1 , R, R a , R b , R c , R d , b and c have the meanings as specified for formula 1, and R' means -CHO or =O, and, optionally, the hydrolysis of the obtained ester of formula 1. The invention also relates to an intermediate compound of formula 2 or a salt thereof. The compound of formula 1 according to the invention is intended for use in the preventive and / or therapeutic treatment of a disease or disorder mediated by CXCR3 receptor as a medicament or as part of a pharmaceutical composition. n EFFECT: cycloalkanecarboxylic acid derivatives as CXCR3 receptor antagonists. n 20 cl, 6 tbl, 160 ex |